HBM rises from the ashes as a research partner for drug giants
The cash-strapped company disposed of a factory and an advanced drug pipeline to stay in business, and is now re-positioning itself as a supplier of biomedical services Key Takeaways: HBM…
Recent Articles
RELATED ARTICLES
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK - Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Investors cheer Akeso’s revenue milestone, even as it returns to the red
9926.HK
- As Covid drug cash dwindles, Vigonvita targets new remedies
-
Cancer drug maker Biostar shines on Hong Kong market debut
2563.HK
-
ACM Research straddles growing U.S.-China microchip divide
ACMR.US 688082.SHG
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
